九洲药业公告，第三季度营收为12.9亿元，同比增长7.37%；净利润为2.22亿元，同比增长42.30%。前 三季度营收为41.6亿元，同比增长4.92%；净利润为7.48亿元，同比增长18.51%。 ...

Group 1 - The core point of the news is that Jiuzhou Pharmaceutical experienced a stock price increase of 5.01%, reaching 20.53 CNY per share, with a trading volume of 673 million CNY and a turnover rate of 3.79%, resulting in a total market capitalization of 18.26 billion CNY [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, is primarily engaged in the research, production, and sales of chemical raw materials and pharmaceutical intermediates. The revenue composition includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - From the perspective of major fund holdings, Guolian Fund has one fund heavily invested in Jiuzhou Pharmaceutical. The Guolian Smart Selection Pioneer Stock A (020748) held 40,200 shares in the second quarter, accounting for 0.39% of the fund's net value, making it the third-largest holding. The estimated floating profit today is approximately 39,400 CNY [2] - The Guolian Smart Selection Pioneer Stock A (020748) has a year-to-date return of 33.41%, ranking 1275 out of 4220 in its category, and a one-year return of 42.87%, ranking 892 out of 3857. Since its inception, the fund has achieved a return of 64.42% [2]

Core Insights - The A-share market has seen a significant rally in innovative drug concept stocks, with notable increases in share prices for several companies [1] Group 1: Stock Performance - Guangxi Shengtang (广生堂) experienced a rise of approximately 18% [2] - Shutaishen (舒泰神) increased by over 12% [2] - Jimin Health (济民健康) and Anglikang (昂利康) both hit the 10% daily limit up [2] - Huahai Pharmaceutical (华海药业) rose by over 9% [2] - Frontier Biologics (前沿生物) increased by over 8% [2] - Hanyu Pharmaceutical (翰宇药业) saw a rise of over 7% [2] - Saily Medical (塞力医疗) and Jiuzhou Pharmaceutical (九洲药业) both increased by over 6% [2] Group 2: Market Capitalization and Year-to-Date Performance - Guangxi Shengtang has a market capitalization of 19.2 billion with a year-to-date increase of 269.02% [2] - Shutaishen has a market capitalization of 17.3 billion with a year-to-date increase of 389.07% [2] - Jimin Health has a market capitalization of 5.76 billion with a year-to-date increase of 61.56% [2] - Anglikang has a market capitalization of 8.31 billion with a year-to-date increase of 213.50% [2] - Huahai Pharmaceutical has a market capitalization of 31.4 billion with a year-to-date increase of 18.92% [2] - Frontier Biologics has a market capitalization of 5.544 billion with a year-to-date increase of 51.64% [2] - Hanyu Pharmaceutical has a market capitalization of 19.2 billion with a year-to-date increase of 68.35% [2] - Saily Medical has a market capitalization of 5.628 billion with a year-to-date increase of 270.91% [2] - Jiuzhou Pharmaceutical has a market capitalization of 18.5 billion with a year-to-date increase of 56.50% [2]

Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical experienced a stock price increase of 5.28%, reaching 20.32 CNY per share, with a total market capitalization of 18.074 billion CNY [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The company's main business revenue composition includes 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - New沃 Fund has a significant holding in Jiuzhou Pharmaceutical, with the New沃 Tongying Flexible Allocation Mixed Fund (002564) holding 15,900 shares, accounting for 3.56% of the fund's net value, ranking as the tenth largest holding [2] - The New沃 Tongying Flexible Allocation Mixed Fund was established on September 22, 2016, with a latest scale of 6.8023 million CNY, and has achieved a year-to-date return of 9.96% [2] - The fund's performance over the past year shows a return of 12.66%, ranking 5,474 out of 8,015 in its category, and a cumulative return of 92.14% since inception [2]

华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模261.47亿。今年以来收益15.61%，同 类排名3206/4220；近一年收益10.99%，同类排名3266/3857；成立以来收益13.29%。 华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间13年2天，现任基金资产总规模843.4亿元，任职期间最佳基金回报 165.18%， 任职期间最差基金回报-98.01%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月14日，九洲药业涨5.28%，截至发稿，报20.32元/股，成交2.28亿元，换手率1.30%，总市值180.74 亿元。 资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 2.72%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which declined by 2.62% [4][16] - The industry valuation as of September 30, 2025, is a PE (TTM overall method, excluding negative values) of 31.23x, down from 31.79x in the previous period, indicating a downward trend and below the average [21] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (55.74x), medical devices (41.29x), and hospitals (39.51x), with the median at 33.19x, while pharmaceutical circulation has the lowest valuation at 14.34x [21] Industry Review - The report highlights that during the reporting period, 51 listed companies in the pharmaceutical and biotechnology sector had a net reduction in shareholders amounting to 2.435 billion yuan, with 14 companies increasing their holdings by 681 million yuan and 37 companies reducing their holdings by 3.116 billion yuan [4] - The report emphasizes the importance of upcoming clinical data and the strong fundamentals of companies ahead of the ESMO 2025 conference, which is expected to showcase significant clinical research results from various domestic pharmaceutical companies [7][8] Important Industry News - AstraZeneca plans to list on the New York Stock Exchange [6] - The report mentions the approval of a new oral SERD drug by Eli Lilly, marking it as the second such drug approved globally [8][45] - The approval of the first domestic quadrivalent HPV vaccine in China is expected to expand the coverage population and potentially be priced lower than imported versions [8][50][52]

Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]

证券代码：603456 证券简称：九洲药业 公告编号：2025-056 浙江九洲药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 二、说明会召开的时间、地点及方式 1、会议召开时间：2025 年 10 月 16 日（星期四）11:00-12:00 2 、 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开时间：2025 年 10 月 16 日（星期四）11:00-12:00 会议召开方式：上证路演中心网络互动 3、会议召开方式：上证路演中心网络互动 三、公司参加人员 董事兼总裁梅义将先生；董事、执行副总裁兼财务负责人沙裕杰先生；董事、 执行副总裁兼董事会秘书林辉潞先生；独立董事杨立荣 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Jiuzhou Pharmaceutical, including stock price movements and trading volumes [1][2] - As of September 29, Jiuzhou Pharmaceutical's stock price increased by 2.06%, reaching 19.32 CNY per share, with a total market capitalization of 17.184 billion CNY [1] - The company has seen a year-to-date stock price increase of 46.52%, with a 1.68% rise over the last five trading days and a 28.87% increase over the last 60 days [1] Group 2 - Jiuzhou Pharmaceutical's main business revenue composition includes 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] - For the first half of 2025, Jiuzhou Pharmaceutical reported a revenue of 2.871 billion CNY, reflecting a year-on-year growth of 3.86%, and a net profit attributable to shareholders of 526 million CNY, up 10.70% [2][3] - The company has distributed a total of 2.183 billion CNY in dividends since its A-share listing, with 1.245 billion CNY distributed in the last three years [3]

Market Overview - On September 25, the medical services sector rose by 0.78%, with Bid Pharma leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Top Gainers in Medical Services - Bid Pharma (688073) closed at 79.56, up 6.61% with a trading volume of 18,000 hands and a transaction value of 141 million [1] - Jiuzhou Pharmaceutical (603456) closed at 19.46, up 5.65% with a trading volume of 749,100 hands and a transaction value of 1.484 billion [1] - Yaokang Bio (688046) closed at 19.10, up 3.24% with a trading volume of 39,200 hands and a transaction value of 74.36 million [1] Top Losers in Medical Services - Baicheng Pharma (301096) closed at 60.30, down 6.37% with a trading volume of 94,600 hands and a transaction value of 583 million [2] - Haochen Medical (002622) closed at 3.83, down 3.04% with a trading volume of 465,400 hands and a transaction value of 181 million [2] - Chengda Pharmaceutical (301201) closed at 29.79, down 2.84% with a trading volume of 33,300 hands and a transaction value of 100 million [2] Capital Flow Analysis - The medical services sector saw a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 28.43 million [2] - Jiuzhou Pharmaceutical had a net inflow of 191 million from institutional investors, but a net outflow of 93.86 million from retail investors [3] - Bid Pharma experienced a net inflow of 19.49 million from institutional investors, with a net outflow of 8.87 million from retail investors [3]